pliva
et
al
mensing
argued
march
decided
june
five
years
food
drug
administration
fda
first
approved
metoclopramide
drug
commonly
used
treat
digestive
tract
problems
brand
name
reglan
generic
manufacturers
petitioners
also
began
producing
drug
accumulating
evidence
metoclopramide
use
cause
tardive
dyskinesia
severe
neurological
disorder
warning
labels
drug
strengthened
clarified
several
times
recently
respondents
prescribed
reglan
received
generic
drug
pharmacists
taking
drug
prescribed
several
years
developed
tardive
dyskinesia
separate
tort
actions
sued
petitioners
generic
drug
manufacturers
produced
metoclopramide
took
manufacturers
respondent
alleged
inter
alia
metoclopramide
use
caused
disorder
manufacturers
liable
state
tort
law
failing
provide
adequate
warning
labels
suits
manufacturers
urged
federal
statutes
fda
regulations
state
tort
claims
requiring
safety
efficacy
labeling
generic
metoclopramide
mandated
time
reglan
fifth
eighth
circuits
rejected
arguments
holding
respondents
claims
held
judgment
reversed
cases
remanded
reversed
remanded
justice
thomas
delivered
opinion
respect
part
concluding
federal
drug
regulations
applicable
generic
drug
manufacturers
directly
conflict
thus
state
claims
pp
analysis
requires
comparison
federal
state
law
begins
identifying
state
tort
duties
federal
labeling
requirements
applicable
manufacturers
pp
state
tort
law
requires
manufacturer
aware
drug
danger
label
way
renders
reasonably
safe
respondents
pleaded
manufacturers
knew
known
use
products
carried
high
risk
tardive
dyskinesia
labels
adequately
warn
risk
taking
allegations
true
duty
required
manufacturers
use
different
stronger
label
one
actually
used
pp
hand
federal
drug
regulations
interpreted
fda
prevented
manufacturers
independently
changing
generic
drugs
safety
labels
manufacturer
seeking
federal
approval
market
new
drug
must
prove
safe
effective
proposed
label
accurate
adequate
although
rules
originally
applied
drugs
law
commonly
called
amendments
allows
generic
drug
manufacturer
gain
fda
approval
simply
showing
drug
equivalent
drug
safety
efficacy
labeling
proposed
drug
approved
drug
respondents
contend
federal
law
nevertheless
provides
avenues
manufacturers
altered
metoclopramide
labels
time
prevent
injuries
include
fda
cbe
process
permits
drug
manufacturers
without
preapproval
add
strengthen
warning
label
sending
dear
doctor
letters
providing
additional
warnings
prescribing
physicians
healthcare
professionals
however
fda
denies
manufacturers
used
either
processes
unilaterally
strengthen
warning
labels
defers
fda
views
plainly
erroneous
inconsistent
regulations
reason
doubt
reflect
fda
fair
considered
judgment
auer
robbins
assuming
without
deciding
fda
correct
federal
law
nevertheless
required
manufacturers
ask
agency
assistance
convincing
manufacturer
adopt
stronger
label
turns
question
pp
state
federal
law
directly
conflict
state
law
must
give
way
see
wyeth
levine
conflict
exists
impossible
private
party
comply
state
federal
requirements
freightliner
myrick
pp
finds
impossibility
manufacturers
independently
changed
labels
satisfy
duty
attach
safer
label
generic
metoclopramide
violated
federal
requirement
generic
drug
labels
corresponding
drug
labels
thus
impossible
comply
state
federal
law
even
fulfilled
federal
duty
ask
fda
help
strengthening
corresponding
label
assuming
duty
exists
satisfied
state
duty
state
law
demanded
safer
label
require
communication
fda
possibility
safer
label
pp
rejects
argument
manufacturers
defense
fails
failed
ask
fda
help
changing
corresponding
label
proper
question
impossibility
analysis
whether
private
party
independently
federal
law
state
law
requires
see
wyeth
supra
accepting
respondents
argument
render
conflict
largely
meaningless
making
conflicts
state
federal
law
illusory
cases
possible
manufacturers
asked
fda
help
might
eventually
able
strengthen
warning
label
also
possible
convinced
fda
reinterpret
regulations
manner
opened
cbe
process
persuaded
fda
rewrite
generic
drug
regulations
entirely
talked
congress
amending
amendments
conjectures
sufficed
prevent
federal
state
law
conflicting
unclear
outside
express
supremacy
clause
force
clause
makes
federal
law
law
land
thing
constitution
laws
state
contrary
notwithstanding
art
vi
cl
read
permit
approach
renders
conflict
meaningless
enough
hold
party
satisfy
state
duties
without
federal
government
special
permission
assistance
dependent
exercise
judgment
federal
agency
party
independently
satisfy
state
duties
purposes
pp
wyeth
contrary
held
state
tort
action
drug
manufacturer
failure
provide
adequate
warning
label
possible
manufacturer
comply
state
federal
law
fda
cbe
regulation
federal
statutes
regulations
apply
drug
manufacturers
differ
congress
design
applicable
generic
drug
manufacturers
different
federal
statutes
regulations
may
lead
different
results
distort
supremacy
clause
order
create
similar
across
dissimilar
statutory
scheme
congress
fda
retain
authority
change
law
regulations
desire
pp
thomas
delivered
opinion
except
part
roberts
scalia
alito
joined
opinion
full
kennedy
joined
part
sotomayor
filed
dissenting
opinion
ginsburg
breyer
kagan
joined
pliva
et
petitioners
gladys
mensing
actavis
elizabeth
llc
petitioner
gladys
mensing
actavis
petitioner
julie
demahy
writs
certiorari
courts
appeals
eighth
fifth
circuits
june
justice
thomas
delivered
opinion
part
consolidated
lawsuits
involve
state
claims
based
certain
drug
manufacturers
alleged
failure
provide
adequate
warning
labels
generic
metoclopramide
question
presented
whether
federal
drug
regulations
applicable
generic
drug
manufacturers
directly
conflict
thus
claims
hold
metoclopramide
drug
designed
speed
movement
food
digestive
system
food
drug
administration
fda
first
approved
metoclopramide
tablets
brand
name
reglan
five
years
later
generic
manufacturers
also
began
producing
drug
commonly
used
treat
digestive
tract
problems
diabetic
gastroparesis
gastroesophageal
reflux
disorder
evidence
accumulated
metoclopramide
use
cause
tardive
dyskinesia
severe
neurological
disorder
studies
shown
patients
take
metoclopramide
several
years
develop
condition
mcneil
wyeth
see
also
shaffer
butterfield
pamer
mackey
tardive
dyskinesia
risks
metoclopramide
use
market
withdrawal
cisapride
pharmacists
assn
noting
cases
tardive
dyskinesia
reported
fda
adverse
event
reporting
system
accordingly
warning
labels
drug
strengthened
clarified
several
times
label
modified
warn
tardive
dyskinesia
may
develop
patients
treated
metoclopramide
drug
package
insert
added
herapy
longer
weeks
evaluated
recommended
physician
desk
reference
ed
see
also
brief
petitioner
pliva
et
al
hereinafter
pliva
brief
reglan
manufacturer
requested
fda
approved
label
change
add
herapy
exceed
weeks
duration
brief
amicus
curiae
hereinafter
brief
fda
ordered
black
box
warning
strongest
treatment
metoclopramide
cause
tardive
dyskinesia
serious
movement
disorder
often
irreversible
treatment
metoclopramide
longer
weeks
avoided
rare
cases
see
physician
desk
reference
ed
gladys
mensing
julie
demahy
plaintiffs
consolidated
cases
prescribed
reglan
respectively
received
generic
metoclopramide
pharmacists
taking
drug
prescribed
several
years
women
developed
tardive
dyskinesia
separate
suits
mensing
demahy
sued
generic
drug
manufacturers
produced
metoclopramide
took
manufacturers
alleged
relevant
metoclopramide
use
caused
dyskinesia
manufacturers
liable
state
tort
law
specifically
minnesota
louisiana
failing
provide
adequate
warning
labels
claimed
despite
mounting
evidence
long
term
metoclopramide
use
carries
risk
tardive
dyskinesia
far
greater
indicated
label
none
manufacturers
changed
labels
adequately
warn
danger
mensing
wyeth
see
also
demahy
actavis
suits
manufacturers
urged
federal
law
state
tort
claims
according
manufacturers
federal
statutes
fda
regulations
required
use
safety
efficacy
labeling
counterparts
means
argued
impossible
simultaneously
comply
federal
law
state
duty
required
use
different
label
courts
appeals
fifth
eighth
circuits
rejected
manufacturers
arguments
held
demahy
claims
see
granted
certiorari
consolidated
cases
reverse
ii
analysis
requires
us
compare
federal
state
law
therefore
begin
identifying
state
tort
duties
federal
labeling
requirements
applicable
manufacturers
undisputed
minnesota
louisiana
tort
law
require
drug
manufacturer
aware
product
danger
label
product
way
renders
reasonably
safe
minnesota
law
applies
mensing
lawsuit
manufacturer
product
actual
constructive
knowledge
danger
users
manufacturer
duty
give
warning
dangers
frey
montgomery
ward
similarly
louisiana
law
applicable
demahy
lawsuit
manufacturer
duty
warn
includes
duty
provide
adequate
instructions
safe
use
product
stahl
novartis
pharmaceuticals
see
also
la
rev
stat
ann
west
duty
warn
falls
specifically
manufacturer
see
marks
ohmeda
pp
la
app
gray
badger
min
mensing
demahy
pleaded
manufacturers
knew
known
high
risk
tardive
dyskinesia
inherent
use
product
also
pleaded
manufacturers
knew
known
labels
adequately
warn
risk
app
parties
dispute
allegations
true
state
law
required
manufacturers
use
different
safer
label
federal
law
imposes
far
complex
drug
labeling
requirements
begin
dispute
drug
amendments
federal
food
drug
cosmetic
act
stat
et
manufacturer
seeking
federal
approval
market
new
drug
must
prove
safe
effective
proposed
label
accurate
see
wyeth
levine
meeting
requirements
involves
costly
lengthy
clinical
testing
see
also
beers
generic
innovator
drugs
guide
fda
approval
requirements
ed
originally
rules
applied
drugs
however
congress
passed
drug
price
competition
patent
term
restoration
act
stat
commonly
called
amendments
law
generic
drugs
gain
fda
approval
simply
showing
equivalence
reference
listed
drug
already
approved
allows
manufacturers
develop
generic
drugs
without
duplicating
clinical
trials
already
performed
equivalent
drug
generic
drug
application
must
also
show
safety
efficacy
labeling
proposed
labeling
approved
drug
see
also
beers
result
generic
drug
manufacturers
different
federal
drug
labeling
duties
manufacturer
seeking
new
drug
approval
responsible
accuracy
adequacy
label
see
wyeth
supra
manufacturer
seeking
generic
drug
approval
hand
responsible
ensuring
warning
label
brand
name
see
cfr
parties
disagree
dispute
whether
extent
generic
manufacturers
may
change
labels
initial
fda
approval
mensing
demahy
contend
federal
law
provided
several
avenues
manufacturers
altered
metoclopramide
labels
time
prevent
injuries
fda
however
tells
us
interprets
regulations
require
warning
labels
drug
generic
copy
must
always
thus
generic
drug
manufacturers
ongoing
federal
duty
sameness
brief
see
also
fed
reg
generic
drug
labeling
must
listed
drug
product
labeling
listed
drug
product
basis
generic
drug
fda
views
controlling
unless
plainly
erroneous
inconsistent
regulation
reason
doubt
reflect
fda
fair
considered
judgment
auer
robbins
internal
quotation
marks
omitted
first
mensing
demahy
urge
fda
cbe
process
allowed
manufacturers
change
labels
necessary
see
brief
respondents
see
also
gaeta
perrigo
pharmaceuticals
foster
american
home
prods
cbe
process
permits
drug
manufacturers
add
strengthen
contraindication
warning
precaution
cfr
iii
add
strengthen
instruction
dosage
administration
intended
increase
safe
use
drug
product
iii
making
labeling
changes
using
cbe
process
drug
need
wait
preapproval
fda
ordinarily
necessary
change
label
wyeth
supra
need
simultaneously
file
supplemental
application
fda
cfr
fda
denies
manufacturers
used
cbe
process
unilaterally
strengthen
warning
labels
agency
interprets
cbe
regulation
allow
changes
generic
drug
labels
generic
drug
manufacturer
changes
label
match
updated
label
follow
fda
instructions
brief
interpreting
cfr
iv
brief
fda
argues
cbe
changes
unilaterally
made
strengthen
generic
drug
warning
label
violate
statutes
regulations
requiring
generic
drug
label
match
counterpart
see
also
cfr
iii
approval
may
withdrawn
generic
drug
label
longer
consistent
defer
fda
interpretation
cbe
generic
labeling
regulations
although
mensing
demahy
offer
ways
interpret
regulations
see
brief
respondents
find
agency
interpretation
plainly
erroneous
inconsistent
regulation
auer
supra
internal
quotation
marks
omitted
mensing
demahy
suggest
reason
doubt
agency
reading
therefore
conclude
cbe
process
open
manufacturers
sort
change
required
state
law
next
mensing
demahy
contend
manufacturers
used
dear
doctor
letters
send
warnings
prescribing
physicians
healthcare
professionals
see
brief
respondents
cfr
fda
disagrees
defer
agency
views
fda
argues
dear
doctor
letters
qualify
labeling
brief
see
also
cfr
thus
letters
must
consistent
contrary
drug
approved
labeling
cfr
dear
doctor
letter
contained
substantial
new
warning
information
consistent
drug
approved
labeling
moreover
generic
drug
manufacturers
manufacturer
sent
letters
inaccurately
imply
therapeutic
difference
brand
generic
drugs
thus
impermissibly
misleading
brief
see
cfr
fda
may
withdraw
approval
generic
drug
labeling
drug
false
misleading
particular
cbe
regulation
defer
fda
mensing
demahy
offer
argument
fda
interpretation
plainly
erroneous
see
auer
accordingly
conclude
federal
law
permit
manufacturers
issue
additional
warnings
dear
doctor
letters
though
fda
denies
manufacturers
used
cbe
process
dear
doctor
letters
strengthen
warning
labels
agency
asserts
different
avenue
existed
changing
generic
drug
labels
according
fda
manufacturers
proposed
indeed
required
propose
stronger
warning
labels
agency
believed
warnings
needed
brief
fed
reg
fda
agreed
label
change
necessary
worked
manufacturer
create
new
label
generic
drug
ibid
agency
traces
duty
provides
drug
misbranded
nless
labeling
bears
adequate
warnings
unsafe
dosage
methods
duration
administration
application
manner
form
necessary
protection
users
see
brief
regulation
fda
interpreted
statute
require
labeling
shall
revised
include
warning
soon
reasonable
evidence
association
serious
hazard
drug
cfr
according
fda
requirements
apply
drugs
explains
premise
federal
drug
regulation
manufacturer
bears
responsibility
content
label
times
brief
quoting
wyeth
fda
reconciles
duty
adequate
accurate
labeling
duty
sameness
following
way
generic
drug
manufacturers
become
aware
safety
problems
must
ask
agency
work
toward
strengthening
label
applies
generic
equivalent
drug
brief
manufacturers
fda
disagree
whether
alleged
duty
request
strengthened
label
actually
existed
fda
argues
explained
duty
preamble
regulations
implementing
amendments
ibid
see
fed
reg
generic
drug
manufacturer
believes
new
safety
information
added
product
labeling
contact
fda
fda
determine
whether
labeling
generic
listed
drugs
revised
manufacturers
claim
fda
statement
create
duty
generic
drug
manufacturer
ever
acting
pursuant
duty
see
tr
oral
arg
reply
brief
petitioner
pliva
et
al
ultimately
find
even
assuming
duty
existed
resolve
matter
summarize
relevant
state
federal
requirements
state
tort
law
places
duty
directly
drug
manufacturers
adequately
safely
label
products
taking
mensing
demahy
allegations
true
duty
required
manufacturers
use
different
stronger
label
label
actually
used
federal
drug
regulations
interpreted
fda
prevented
manufacturers
independently
changing
generic
drugs
safety
labels
assume
federal
law
also
required
manufacturers
ask
fda
assistance
convincing
manufacturer
adopt
stronger
label
corresponding
generic
drug
manufacturers
well
turn
question
iii
supremacy
clause
establishes
federal
law
shall
law
land
thing
constitution
laws
state
contrary
notwithstanding
art
vi
cl
state
federal
law
directly
conflict
state
law
must
give
way
wyeth
supra
thomas
concurring
judgment
see
also
crosby
national
foreign
trade
council
tate
law
naturally
preempted
extent
conflict
federal
statute
held
state
federal
law
conflict
impossible
private
party
comply
state
federal
requirements
freightliner
myrick
internal
quotation
marks
omitted
find
impossibility
lawful
federal
law
manufacturers
state
law
required
even
fulfilled
federal
duty
ask
fda
assistance
satisfied
requirements
state
law
manufacturers
independently
changed
labels
satisfy
duty
violated
federal
law
taking
mensing
demahy
allegations
true
state
law
imposed
duty
attach
safer
label
generic
metoclopramide
federal
law
however
demanded
drug
labels
times
drug
labels
see
cfr
thus
impossible
manufacturers
comply
duty
change
label
federal
law
duty
keep
label
federal
duty
ask
fda
help
strengthening
corresponding
label
assuming
duty
exists
change
analysis
although
requesting
fda
assistance
satisfied
federal
duty
satisfied
state
duty
provide
adequate
labeling
state
law
demanded
safer
label
instruct
manufacturers
communicate
fda
possibility
safer
label
indeed
mensing
demahy
deny
state
tort
claims
based
manufacturers
alleged
failure
ask
fda
assistance
changing
labels
brief
respondents
cf
buckman
plaintiffs
legal
holding
federal
drug
medical
device
laws
state
claim
based
failure
properly
communicate
fda
mensing
demahy
contend
claims
turn
whether
manufacturers
asked
fda
assistance
changing
labels
manufacturers
federal
affirmative
defense
mensing
demahy
argue
manufacturers
asked
fda
help
changing
corresponding
label
might
eventually
able
accomplish
federal
law
state
law
requires
true
enough
manufacturers
freely
concede
asked
fda
help
pliva
brief
done
fda
decided
sufficient
supporting
information
fda
undertook
negotiations
manufacturer
adequate
label
changes
decided
implemented
manufacturers
started
mouse
trap
game
eventually
led
better
label
generic
metoclopramide
raises
novel
question
whether
conflict
take
account
possible
actions
fda
manufacturer
federal
law
permitted
manufacturers
changed
even
absent
change
law
depending
actions
fda
manufacturer
federal
law
dictate
text
generic
drug
label
rather
ties
labels
counterparts
thus
federal
law
permit
manufacturers
comply
state
labeling
requirements
fda
manufacturer
changed
label
mensing
demahy
assert
private
party
ability
comply
state
law
depends
approval
assistance
fda
proving
requires
party
demonstrate
fda
allowed
compliance
state
law
argue
manufacturers
bear
burden
proving
impossibility
even
try
start
process
might
ultimately
allowed
use
safer
label
brief
respondents
fair
argument
reject
question
impossibility
whether
private
party
independently
federal
law
state
law
requires
see
wyeth
finding
defendant
unilaterally
state
law
required
accepting
mensing
demahy
argument
render
conflict
largely
meaningless
make
conflicts
state
federal
law
illusory
often
imagine
third
party
federal
government
might
something
makes
lawful
private
party
accomplish
federal
law
state
law
requires
cases
certainly
possible
manufacturers
asked
fda
help
might
eventually
able
strengthen
warning
label
course
also
possible
manufacturers
convinced
fda
reinterpret
regulations
manner
opened
cbe
process
following
mensing
demahy
argument
logical
conclusion
also
possible
asking
manufacturers
persuaded
fda
rewrite
generic
drug
regulations
entirely
talked
congress
amending
amendments
conjectures
suffice
prevent
federal
state
law
conflicting
supremacy
clause
purposes
unclear
outside
express
supremacy
clause
read
supremacy
clause
permit
approach
renders
conflict
meaningless
supremacy
clause
face
makes
federal
law
law
land
even
absent
express
statement
congress
art
vi
cl
moreover
text
clause
federal
law
shall
thing
constitution
laws
state
contrary
notwithstanding
plainly
contemplates
conflict
describing
federal
law
effectively
repealing
contrary
state
law
ibid
see
nelson
preemption
rev
describing
discussion
supremacy
clause
state
ratification
debates
concerning
whether
federal
law
repeal
state
law
vice
versa
phrase
state
law
contrary
notwithstanding
non
provision
nn
legislatures
used
non
obstante
provisions
specify
degree
new
statute
meant
repeal
older
potentially
conflicting
statutes
field
citing
dozens
statutes
similar
provisions
non
obstante
provision
new
statute
acknowledged
statute
might
contradict
prior
law
instructed
courts
apply
general
presumption
implied
repeals
bacon
new
abridgment
law
ed
although
two
acts
parliament
seemingly
repugnant
yet
clause
non
obstante
latter
shall
possible
construction
latter
may
repeal
former
implication
non
obstante
provision
supremacy
clause
therefore
suggests
federal
law
understood
impliedly
repeal
conflicting
state
law
provision
suggests
courts
strain
find
ways
reconcile
federal
law
seemingly
conflicting
state
law
traditionally
courts
went
great
lengths
attempting
harmonize
conflicting
statutes
order
avoid
implied
repeals
warder
arell
opinion
roane
seek
construction
reconcile
statutes
together
ludlow
heirs
johnston
ohio
fair
course
reasoning
two
statutes
reconciled
shall
stand
doolittle
bryan
requiring
repugnance
quite
plain
finding
implied
repeal
non
obstante
provision
thus
useful
way
legislatures
specify
want
courts
distorting
new
law
accommodate
old
nelson
supra
see
also
sutherland
statutes
statutory
construction
hen
inserted
statute
provision
non
obstante
supposed
courts
less
inclined
recognizing
repugnancy
applying
statutes
weston
case
eng
hen
two
statutes
one
appearance
crossing
clause
non
obstante
contained
second
statute
exposition
stand
force
jacob
new
law
dictionary
morgan
ed
definition
statute
hen
seeming
variance
two
statutes
clause
non
obstante
latter
construction
shall
made
may
stand
non
obstante
provision
supremacy
clause
indicates
need
look
ordinary
meanin
federal
law
distort
federal
law
accommodate
conflicting
state
law
wyeth
thomas
concurring
judgment
internal
quotation
marks
omitted
consider
analysis
contingencies
inherent
cases
manufacturers
ability
comply
state
law
depended
uncertain
federal
agency
decisions
inconsistent
non
obstante
provision
supremacy
clause
manufacturers
required
continually
prove
counterfactual
conduct
fda
manufacturer
order
establish
supremacy
federal
law
think
supremacy
clause
contemplates
sort
contingent
supremacy
non
obstante
provision
suggests
analysis
involve
speculation
ways
federal
agency
actions
potentially
reconcile
federal
duties
conflicting
state
duties
ordinary
meaning
federal
law
blocks
private
party
independently
accomplishing
state
law
requires
party
established
sure
whether
private
party
act
sufficiently
independently
federal
law
state
law
requires
may
sometimes
difficult
determine
case
manufacturers
satisfy
state
law
fda
federal
agency
undertake
special
effort
permitting
decide
cases
enough
hold
party
satisfy
state
duties
without
federal
government
special
permission
assistance
dependent
exercise
judgment
federal
agency
party
independently
satisfy
state
duties
purposes
state
law
imposed
duty
manufacturers
take
certain
action
federal
law
barred
taking
action
action
manufacturers
independently
take
asking
fda
help
matter
concern
mensing
demahy
tort
claims
wyeth
contrary
case
plaintiff
contended
drug
manufacturer
breached
state
duty
provide
adequate
warning
label
held
lawsuit
possible
wyeth
drug
manufacturer
comply
state
federal
law
specifically
cbe
regulation
cfr
iii
permitted
drug
manufacturer
like
wyeth
unilaterally
strengthen
warning
without
prior
fda
approval
cf
supra
thus
federal
regulations
applicable
wyeth
allowed
company
volition
strengthen
label
compliance
state
tort
recognize
perspective
mensing
demahy
finding
wyeth
makes
little
sense
mensing
demahy
taken
reglan
drug
prescribed
doctors
wyeth
control
lawsuits
pharmacists
acting
full
accord
state
law
substituted
generic
metoclopramide
instead
federal
law
lawsuits
see
stat
describing
pharmacists
may
substitute
drugs
la
rev
stat
ann
west
acknowledge
unfortunate
hand
federal
drug
regulation
dealt
mensing
demahy
others
similarly
task
decide
whether
statutory
scheme
established
congress
unusual
even
bizarre
cuomo
clearing
house
thomas
concurring
part
dissenting
part
slip
internal
quotation
marks
brackets
omitted
beyond
dispute
federal
statutes
regulations
apply
drug
manufacturers
meaningfully
different
apply
generic
drug
manufacturers
indeed
special
different
regulation
generic
drugs
allowed
generic
drug
market
expand
bringing
drugs
quickly
cheaply
public
different
federal
statutes
regulations
may
lead
different
results
distort
supremacy
clause
order
create
similar
across
dissimilar
statutory
scheme
always
congress
fda
retain
authority
change
law
regulations
desire
judgments
fifth
eighth
circuits
reversed
cases
remanded
proceedings
consistent
opinion
ordered
pliva
et
petitioners
gladys
mensing
actavis
elizabeth
llc
petitioner
gladys
mensing
actavis
petitioner
julie
demahy
writs
certiorari
courts
appeals
eighth
fifth
circuits
june
justice
sotomayor
justice
ginsburg
justice
breyer
justice
kagan
join
dissenting
today
invokes
doctrine
impossibility
hold
federal
law
immunizes
manufacturers
claims
unilaterally
change
agree
traditionally
held
defendants
claiming
impossibility
demanding
standard
today
mere
possibility
impossibility
enough
establish
food
drug
administration
fda
permits
assumes
requires
manufacturers
propose
label
change
fda
believe
labels
inadequate
agrees
labels
inadequate
fda
initiate
change
label
triggering
corresponding
change
generic
labels
occurs
generic
manufacturer
full
compliance
federal
law
duty
warn
although
generic
manufacturers
may
able
show
impossibility
cases
petitioners
generic
manufacturers
metoclopramide
manufacturers
shown
might
unable
comply
federal
law
duties
warn
respondents
gladys
mensing
julie
demahy
hold
insufficient
sustain
burden
strains
reach
opposite
conclusion
invents
new
principles
law
thin
air
justify
dilution
impossibility
standard
effectively
rewrites
decision
wyeth
levine
holds
federal
law
claims
drug
manufacturers
plurality
tosses
aside
repeated
admonition
courts
hesitate
conclude
congress
intended
state
laws
governing
health
safety
result
today
decision
whether
consumer
harmed
inadequate
warnings
obtain
relief
turns
solely
happenstance
whether
pharmacist
filled
prescription
generic
drug
gets
one
thing
right
outcome
makes
little
sense
ante
today
decision
affects
percent
prescription
drugs
dispensed
country
dominant
position
generic
drugs
prescription
drug
market
result
series
legislative
measures
federal
state
congress
enacted
drug
price
competition
patent
term
restoration
act
stat
commonly
known
amendments
federal
food
drug
cosmetic
act
fdca
make
available
low
cost
generic
drugs
establishing
generic
drug
approval
procedure
pt
majority
explains
accomplish
goal
amendments
establish
abbreviated
application
process
generic
drugs
ante
see
also
abbreviated
approval
process
implements
amendments
core
principle
generic
drugs
must
nearly
respects
obtain
fda
approval
generic
manufacturer
must
ordinarily
show
among
things
product
active
ingredients
approved
drug
route
dosage
form
strength
new
drug
drug
product
bioequivalent
drug
ii
iii
iv
eliminating
need
generic
manufacturers
prove
drugs
safety
efficacy
independently
amendments
allow
generic
manufacturers
bring
drugs
market
much
less
expensively
also
acted
expand
consumption
generic
drugs
years
leading
passage
amendments
enacted
legislation
authorizing
pharmacists
substitute
generic
drugs
filling
prescriptions
drugs
christensen
kirking
ascione
welage
gaither
drug
product
selection
legal
issues
pharmaceutical
assn
currently
form
generic
substitution
law
see
ibid
require
generic
substitution
certain
circumstances
dept
health
human
aspe
issue
brief
expanding
use
generic
drugs
hereinafter
expanding
use
generic
drugs
see
educ
law
ann
west
others
permit
require
substitution
expanding
use
generic
drugs
see
cal
bus
code
ann
west
supp
require
patient
consent
substitution
allow
physician
specify
brand
name
must
prescribed
although
different
levels
effort
physician
expanding
use
generic
drugs
legislative
efforts
expand
production
consumption
generic
drugs
proved
wildly
successful
estimated
amendments
enacted
generic
drugs
constituted
percent
drugs
sold
country
congressional
office
increased
competition
generic
drugs
affected
prices
returns
pharmaceutical
industry
today
dominate
market
see
expanding
use
generic
drugs
generic
drugs
constituted
percent
dispensed
prescription
drugs
ninety
percent
drugs
generic
version
available
filled
generics
many
cases
generic
versions
drug
enter
market
manufacturer
stops
selling
drug
altogether
see
brief
marc
law
et
al
amici
curiae
citing
studies
showing
anywhere
generic
drugs
longer
marketed
equivalent
reflecting
success
products
many
generic
manufacturers
including
manufacturers
amici
huge
multinational
companies
total
generic
drug
manufacturers
sold
estimated
billion
drugs
country
see
noted
obtain
fda
approval
generic
manufacturer
must
generally
show
drug
approved
drug
need
conduct
clinical
trials
prove
safety
efficacy
drug
mean
however
generic
manufacturer
duty
federal
law
ensure
safety
products
fda
limited
resources
conduct
postapproval
monitoring
drug
safety
see
wyeth
manufacturers
recognized
superior
access
information
drugs
especially
postmarketing
phase
new
risks
emerge
federal
law
thus
obliges
drug
manufacturers
generic
monitor
safety
products
federal
law
generic
manufacturers
must
develop
written
procedures
surveillance
receipt
evaluation
reporting
postmarketing
adverse
drug
experiences
cfr
see
also
making
applicable
generic
manufacturers
brief
amicus
curiae
hereinafter
brief
must
review
reports
adverse
drug
experiences
received
source
manufacturer
receives
report
serious
unexpected
adverse
drug
experience
must
event
fda
within
days
must
promptly
investigate
ii
see
also
tr
oral
arg
adverse
drug
experiences
must
reported
quarterly
yearly
generic
manufacturers
must
also
submit
fda
annual
report
summarizing
significant
new
information
previous
year
might
affect
safety
labeling
drug
product
including
description
actions
manufacturer
taken
intends
take
result
new
information
see
also
generic
manufacturers
majority
assumes
also
bear
responsibility
federal
law
monitoring
adequacy
warnings
agree
majority
conclusion
generic
manufacturers
permitted
unilaterally
change
labels
cbe
process
issue
additional
warnings
dear
doctor
letters
see
ante
according
fda
however
generic
manufacturers
disseminate
additional
warnings
mean
federal
law
permits
remain
idle
conclude
labeling
inadequate
fda
regulations
require
labeling
revised
include
warning
soon
reasonable
evidence
association
serious
hazard
drug
cfr
currently
codified
cfr
see
also
wyeth
fda
construes
regulation
oblige
generic
manufacturers
seek
revise
labeling
provide
fda
supporting
information
risks
believe
additional
warnings
brief
manufacturers
disagree
read
fda
regulation
require
ensure
labels
match
labels
see
brief
petitioner
pliva
et
al
need
decide
whether
regulation
fact
obliges
generic
manufacturers
approach
fda
propose
label
change
majority
assumes
even
generic
manufacturers
duty
propose
label
changes
two
points
remain
undisputed
first
duty
federal
law
monitor
safety
products
second
may
approach
fda
propose
label
change
believe
change
required
ii
brings
manufacturers
defense
state
law
obliged
manufacturers
warn
dangers
users
see
hines
remington
arms
la
frey
montgomery
ward
manufacturers
contend
majority
agrees
federal
law
respondents
claims
federal
law
provided
additional
warnings
respondents
without
exercise
judgment
fda
endorse
novel
conception
impossibility
two
principles
guide
analysis
first
purpose
congress
ultimate
touchstone
every
case
wyeth
quoting
medtronic
lohr
second
cases
particularly
congress
legislated
field
traditionally
occupied
start
assumption
historic
police
powers
superseded
federal
act
unless
clear
manifest
purpose
congress
wyeth
quoting
lohr
internal
quotation
marks
omitted
alterations
original
principles
find
particular
resonance
cases
traditionally
regulated
health
safety
matters
see
notwithstanding
congress
certain
awareness
prevalence
state
tort
litigation
drug
manufacturers
wyeth
congress
expressly
tort
actions
prescription
drug
manufacturers
whether
generic
contrary
congress
amended
fdca
enlarg
fda
powers
public
health
safety
effectiveness
reliability
drugs
took
care
preserve
state
law
quoting
stat
see
pub
stat
nothing
amendments
made
act
fdca
shall
construed
invalidating
provision
state
law
valid
absence
amendments
unless
direct
positive
conflict
amendments
provision
state
law
notably
although
congress
enacted
express
provision
medical
devices
see
pub
stat
included
provision
amendments
eight
years
later
cf
wyeth
congress
silence
issue
powerful
evidence
intend
fda
oversight
exclusive
means
ensuring
drug
safety
effectiveness
federal
law
impliedly
state
law
state
federal
law
conflict
impossible
private
party
comply
state
federal
law
state
law
stands
obstacle
accomplishment
execution
full
purposes
objectives
congress
crosby
national
foreign
trade
council
internal
quotation
marks
omitted
manufacturers
rely
solely
former
ground
impossibility
emphasized
defense
wyeth
affirmative
defense
defendant
seeking
set
aside
state
law
bears
burden
prove
impossibility
see
ibid
silkwood
prevail
defense
defendant
must
demonstrate
compliance
federal
state
law
physical
impossibility
florida
lime
avocado
growers
paul
see
also
wyeth
words
must
inevitable
collision
federal
state
law
florida
lime
existence
hypothetical
potential
conflict
insufficient
warrant
state
law
rice
norman
williams
see
also
gade
national
solid
wastes
management
kennedy
concurring
part
concurring
judgment
words
mere
possibility
impossibility
enough
manufacturers
contend
impossible
provide
additional
warnings
respondents
demahy
federal
law
prohibited
changing
labels
concede
however
asked
fda
initiate
label
change
fda
agreed
label
change
required
asked
indeed
pressured
manufacturer
change
label
triggering
corresponding
change
manufacturers
generic
thus
manufacturers
invoked
available
mechanism
initiating
label
changes
may
well
able
change
labels
sufficient
time
warn
respondents
failed
manufacturers
sustain
burden
least
without
factual
development
demonstrate
impossible
comply
federal
state
law
demonstrated
hypothetical
potential
conflict
rice
like
majority
manufacturers
focus
fact
change
labels
unilaterally
distinguishes
defendant
wyeth
correctly
point
wyeth
concluded
fda
cbe
regulation
authorized
defendant
strengthen
warnings
receiving
agency
approval
supplemental
application
describing
label
change
see
also
cfr
defendant
label
change
contingent
fda
acceptance
fda
retained
authority
reject
labeling
changes
made
pursuant
cbe
regulation
wyeth
thus
long
run
manufacturer
compliance
duty
warn
required
action
two
actors
manufacturer
change
label
fda
upon
reviewing
supplemental
application
agree
need
fda
approval
label
change
make
compliance
federal
state
law
impossible
every
case
instead
defendant
bore
burden
show
impossibility
required
produce
clear
evidence
fda
approved
change
label
ibid
apply
approach
cases
state
law
respondents
allege
required
manufacturers
provide
strengthened
warning
dangers
metoclopramide
like
manufacturer
wyeth
manufacturers
available
mechanism
attempting
comply
duty
warn
federal
law
thus
accommodated
manufacturers
duties
see
ante
necessarily
impossible
manufacturers
comply
federal
state
law
approached
fda
fda
may
well
agreed
label
change
necessary
accordingly
wyeth
require
manufacturers
show
fda
approved
proposed
label
change
made
showing
argue
attempted
give
kind
warning
required
state
law
prohibited
fda
wyeth
say
generic
manufacturers
never
show
impossibility
defendant
proposed
label
change
fda
fda
rejected
proposal
impossible
defendant
comply
duty
warn
likewise
impossibility
established
fda
yet
responded
generic
manufacturer
request
label
change
time
plaintiff
injuries
arose
generic
manufacturer
might
also
show
fda
considered
whether
request
enhanced
warnings
light
evidence
plaintiff
claim
rests
decided
leave
warnings
manufacturers
make
argument
cases
see
brief
petitioner
actavis
et
al
questions
fact
established
discovery
burden
proving
impossibility
falls
defendant
hold
federal
law
render
impossible
generic
manufacturers
comply
duty
warn
categorical
matter
conclusion
flows
naturally
overarching
governing
doctrine
see
supra
respect
sovereigns
federal
system
leads
us
assume
cavalierly
causes
action
wyeth
quoting
lohr
reason
hold
defendants
asserting
impossibility
demanding
standard
wyeth
presumption
particular
force
federal
government
afforded
defendants
mechanism
complying
state
law
even
mechanism
requires
federal
agency
action
presumption
even
greater
force
federal
law
requires
defendants
invoke
mechanism
majority
assumes
cases
circumstances
hold
defendants
usually
unable
sustain
burden
showing
impossibility
even
attempted
employ
mechanism
approach
threatens
infringe
authority
traditional
matters
state
interest
claims
congress
expressed
intent
state
law
majority
concedes
manufacturers
might
able
accomplish
federal
law
state
law
requires
ante
reach
conclusion
manufacturers
nonetheless
satisfied
show
impossibility
majority
invents
new
rule
question
whether
private
party
independently
federal
law
state
law
requires
ante
emphasis
added
manufacturers
changed
labels
without
exercise
judgment
fda
majority
holds
compliance
state
federal
law
impossible
majority
new
test
basis
precedents
majority
cites
wyeth
support
test
discussed
however
wyeth
stand
proposition
impossible
comply
federal
state
law
whenever
federal
agency
approval
required
contrary
label
changes
manufacturers
wyeth
subject
fda
review
acceptance
see
supra
even
wyeth
characterized
turning
fact
manufacturer
change
label
unilaterally
possibility
unilateral
action
sufficient
condition
rejecting
impossibility
defense
case
wyeth
hold
unilateral
action
necessary
condition
every
case
little
support
case
law
majority
turns
rationales
none
rationales
offers
however
makes
sense
first
offers
reductio
ad
absurdum
possibility
fda
approval
label
change
sufficient
avoid
conflict
cases
warns
logical
conclusion
possibility
fda
might
rewrite
regulations
congress
might
amend
amendments
ante
logic
conclusion
escapes
conflict
analysis
necessarily
turns
existing
law
thus
ridiculous
conclude
federal
state
law
conflict
ground
defendant
asked
federal
agency
congress
change
law
contrast
manufacturers
compliance
duty
warn
ask
change
federal
law
majority
recognizes
see
ante
ederal
law
permit
manufacturers
comply
state
labeling
requirements
fda
manufacturer
changed
label
fda
already
afforded
mechanism
attempting
comply
duties
indeed
majority
assumes
fda
regulations
required
manufacturers
request
label
change
reasonable
evidence
association
serious
hazard
drug
cfr
second
majority
suggests
approach
render
conflict
illusory
ante
expresses
concern
without
robust
view
constitutes
conflict
supremacy
clause
force
except
cases
express
ibid
extent
majority
purported
concern
driven
reductio
ad
absurdum
see
ante
concern
illusory
reasons
stated
extent
majority
concerned
traditionally
narrow
view
constitutes
impossibility
somehow
renders
conflict
whole
meaningless
concern
simply
makes
sense
repeatedly
recognized
conflict
may
found
even
absent
impossibility
state
law
stands
obstacle
accomplishment
execution
full
purposes
objectives
congress
crosby
internal
quotation
marks
omitted
see
geier
american
honda
motor
barnett
bank
marion
nelson
hines
davidowitz
majority
expansive
view
impossibility
thus
unnecessary
prevent
conflict
losing
third
plurality
adopts
novel
theory
framers
intended
supremacy
clause
operate
non
obstante
provision
see
ante
citing
nelson
preemption
rev
according
plurality
non
obstante
provisions
statutes
instruc
courts
apply
general
presumption
implied
repeals
ante
internal
quotation
marks
omitted
see
also
ante
stating
statute
contains
non
obstante
provision
less
inclined
recognizing
repugnancy
applying
quoting
sutherland
statutes
statutory
construction
understanding
supremacy
clause
plurality
extrapolates
principle
courts
strain
find
ways
reconcile
federal
law
seemingly
conflicting
state
law
ante
principle
news
congress
enacted
amendments
precedents
hold
opposite
half
century
directed
courts
presume
congressional
action
supersede
historic
police
powers
unless
clear
manifest
purpose
congress
rice
santa
fe
elevator
see
also
gade
kennedy
concurring
part
concurring
judgment
apply
presumption
congress
spoken
question
see
wyeth
context
express
read
federal
statutes
whenever
possible
state
law
see
altria
group
good
hen
text
clause
susceptible
one
plausible
reading
courts
ordinarily
reading
disfavors
quoting
bates
dow
agrosciences
llc
see
also
cipollone
liggett
group
claim
federal
law
impliedly
state
law
require
strong
showing
conflict
overcome
presumption
state
local
regulation
constitutionally
coexist
federal
regulation
hillsborough
county
automated
medical
laboratories
plurality
new
theory
supremacy
clause
direct
assault
whereas
long
presumed
federal
law
repeal
state
law
plurality
today
reads
supremacy
clause
operate
provision
instructing
courts
apply
general
presumption
implied
repeals
ante
internal
quotation
marks
omitted
emphasis
added
whereas
long
required
evidence
clear
manifest
purpose
rice
plurality
instructs
courts
look
ordinary
meaning
federal
law
concluding
congress
must
intended
cast
aside
state
law
ante
internal
quotation
marks
alteration
omitted
plurality
finds
necessary
resort
novel
theory
supremacy
clause
theory
advocated
party
amici
cases
telling
proper
application
longstanding
presumption
compels
conclusion
federal
law
render
compliance
state
law
impossible
merely
requires
actor
seek
federal
agency
approval
federal
law
provides
actors
attempting
comply
duties
respect
sovereigns
federal
require
actors
attempt
comply
state
law
heard
complain
compliance
laws
impossible
wyeth
quoting
lohr
iii
today
decision
leads
many
absurd
consequences
fathom
congress
intended
state
law
cases
first
majority
analysis
strips
consumers
compensation
injured
inadequate
warnings
congress
intended
deprive
injured
parties
long
available
form
compensation
surely
expressed
intent
clearly
bates
given
longstanding
existence
product
liability
actions
including
failure
warn
difficult
believe
congress
without
comment
remove
means
judicial
recourse
injured
illegal
conduct
silkwood
see
also
bruesewitz
wyeth
llc
slip
noting
previously
expressed
doubt
congress
quietly
preempt
claims
without
providing
federal
substitute
concluding
congress
silently
immunized
generic
manufacturers
claims
majority
disregards
previous
hesitance
infer
congressional
intent
effect
sweeping
change
traditional
remedies
majority
admits
drug
consumer
right
compensation
inadequate
warnings
turns
happenstance
whether
pharmacist
filled
drug
generic
consumer
takes
drug
sue
manufacturer
inadequate
warnings
opinion
wyeth
however
takes
generic
drug
occurs
percent
time
right
sue
majority
offers
reason
think
apart
new
articulation
impossibility
standard
congress
intended
arbitrary
distinction
pharmacists
must
dispense
generic
drugs
absent
instruction
contrary
consumer
physician
even
consumers
request
drugs
price
drug
consumers
insurance
plans
may
make
impossible
result
many
cases
consumers
ability
preserve
right
recover
injuries
caused
inadequate
warnings
second
majority
decision
creates
gap
parallel
regulatory
scheme
way
troubling
consequences
drug
safety
explained
wyeth
tate
tort
suits
uncover
unknown
drug
hazards
provide
incentives
drug
manufacturers
disclose
safety
risks
promptly
thus
recognized
state
law
offers
additional
important
layer
consumer
protection
complements
fda
regulation
ibid
today
decision
eliminates
traditional
incentives
generic
manufacturers
monitor
disclose
safety
risks
generic
drug
equivalent
market
manufacturer
remain
incentivized
uncover
safety
risks
manufacturers
often
leave
market
generic
versions
available
see
supra
meaning
manufacturer
subject
liability
generic
drugs
additional
layer
consumer
protection
wyeth
finally
today
decision
undoes
core
principle
amendments
generic
drugs
nearly
see
brief
henry
waxman
amicus
curiae
majority
pins
expansion
generic
drug
market
special
different
regulation
generic
drugs
allows
generic
manufacturers
produce
drugs
cheaply
ante
tells
half
story
expansion
market
generic
drugs
also
flowed
increased
acceptance
trust
generic
drugs
consumers
physicians
state
legislators
alike
today
decision
introduces
critical
distinction
generic
drugs
consumers
drugs
sue
manufacturers
inadequate
warnings
consumers
generic
drugs
divergent
liability
rules
threaten
reduce
consumer
demand
generics
least
among
consumers
afford
drugs
may
pose
ethical
dilemma
prescribing
physicians
brief
american
medical
association
et
al
amici
curiae
may
well
cause
rethink
longstanding
efforts
promote
generic
use
generic
substitution
laws
see
brief
national
conference
state
legislators
amicus
curiae
state
generic
substitution
laws
proceeded
premise
generic
drugs
citizens
perspective
materially
different
brand
ones
except
lower
price
consequences
directly
odds
amendments
goal
increasing
consumption
generic
drugs
nothing
opinion
convinces
enacting
requirement
generic
labels
match
corresponding
labels
congress
intended
absurd
results
certainly
shown
clear
manifest
purpose
congress
wyeth
internal
quotation
marks
omitted
emphasis
added
contrary
federal
law
affords
generic
manufacturers
mechanism
attempting
comply
duties
warn
hold
federal
law
categorically
claims
generic
manufacturers
especially
light
presumption
burden
fall
generic
manufacturers
show
compliance
impossible
particular
facts
case
holding
possibility
possibility
insufficient
defea
cases
ante
contorts
doctrine
exempts
defendants
burden
establish
impossibility
respect
dissent
footnotes
together
actavis
elizabeth
llc
mensing
also
certiorari
actavis
demahy
certiorari
appeals
fifth
circuit
footnotes
justice
kennedy
joins
part
opinion
relevant
events
cases
predate
food
drug
administration
amendments
act
stat
therefore
refer
exclusively
statutes
regulations
express
view
impact
act
use
generic
drug
refers
drug
designed
copy
reference
listed
drug
typically
drug
thus
identical
active
ingredients
safety
efficacy
see
generix
drug
cfr
defining
reference
listed
drug
brief
filed
represents
views
fda
cf
talk
america
michigan
bell
telephone
slip
chase
bank
usa
mccoy
slip
although
defer
agency
interpretation
regulations
defer
agency
ultimate
conclusion
whether
state
law
wyeth
levine
address
whether
state
federal
law
directly
conflict
circumstances
beyond
impossibility
see
wyeth
thomas
concurring
judgment
suggesting
might
amendments
contain
provision
expressly
state
tort
claims
see
post
sotomayor
dissenting
contain
saving
clause
expressly
preserve
state
tort
claims
cf
williamson
mazda
motor
america
thomas
concurring
judgment
discussing
saving
clause
national
traffic
motor
vehicle
safety
act
although
express
statement
always
preferable
lack
statement
end
inquiry
contrary
dissent
suggestion
absence
express
reason
find
conflict
see
post
dissent
asserts
forgetting
post
dissent
acknowledges
form
conflict
post
conflict
analysis
must
take
account
hypothetical
federal
action
including
possible
changes
acts
congress
little
reason
think
based
purposes
objectives
congress
survive
either
wyeth
also
urged
state
tort
law
creat
ed
unacceptable
accomplishment
execution
full
purposes
objectives
congress
quoting
hines
davidowitz
rejected
argument
type
argued
cf
post
opinion
sotomayor
fda
however
retained
authority
eventually
rescind
wyeth
unilateral
cbe
changes
accordingly
noted
wyeth
attempted
show
clear
evidence
fda
rescinded
change
label
thereby
demonstrate
fact
impossible
federal
law
state
law
required
wyeth
supra
wyeth
offered
evidence
analysis
consistent
holding
today
wyeth
asked
drug
manufacturer
independently
federal
law
absence
clear
evidence
wyeth
accomplished
state
law
required
found
wyeth
held
federal
law
accommodated
state
law
duties
possibility
impossibility
enough
post
see
also
rice
norman
williams
rejecting
hypothetical
impossibility
existing
federal
law
directly
conflicts
state
law
post
conflict
analysis
necessarily
turns
existing
law
question
cases
whether
possibility
impossibility
establishes
rather
whether
possibility
possibility
defeats
post
said
dissent
overstates
characterizes
many
absurd
consequences
holding
post
first
fda
us
practical
matter
genuinely
new
information
drugs
long
use
generic
drugs
typically
appears
brief
patent
protections
ordinarily
prevent
generic
drugs
arriving
market
number
years
drug
appears
indeed
situations
like
one
alleged
apparently
rare
fda
formal
regulation
establishing
generic
drug
manufacturers
duty
initiate
label
change
regulation
setting
process
second
dissent
admits
even
approach
generic
drug
manufacturers
establish
number
scenarios
post
footnotes
online
http
internet
materials
visited
june
available
clerk
case
file
addition
many
insurance
plans
structured
promote
generic
use
see
congressional
budget
office
effects
using
generic
drugs
medicare
prescription
drug
spending
online
http
state
medicaid
programs
similarly
promote
generic
use
see
kaiser
medicaid
uninsured
state
medicaid
outpatient
prescription
drug
policies
findings
national
survey
update
online
online
http
adverse
drug
experience
defined
ny
adverse
event
associated
use
drug
humans
whether
considered
drug
related
cfr
like
majority
refer
statutes
regulations
see
ante
congressional
hearings
amendments
representatives
generic
drug
manufacturers
confirmed
obligation
ability
conduct
postapproval
investigation
adverse
drug
experiences
see
drug
legislation
hearings
et
al
subcommittee
health
environment
house
committee
energy
commerce
statement
kenneth
larsen
chairman
generic
pharmaceutical
industry
association
gpha
generic
manufacturers
sensitive
importance
looking
adverse
reactions
provide
whatever
required
performed
meet
regulatory
requirement
provide
safety
using
drug
role
responsibility
obligation
business
statement
bill
haddad
executive
officer
president
gpha
every
single
generic
drug
company
know
large
research
staff
researches
drug
copying
bringing
market
researches
new
drugs
researches
adverse
reaction
fda
construction
regulation
mirrors
guidance
provided
generic
manufacturers
nearly
years
ago
announcing
final
rule
implementing
abbreviated
application
process
generic
drugs
anda
application
approval
generic
drug
applicant
believes
new
safety
information
added
product
labeling
contact
fda
fda
determine
whether
labeling
generic
listed
drugs
revised
approval
anda
anda
holder
believes
new
safety
information
added
provide
adequate
supporting
information
fda
fda
determine
whether
labeling
generic
listed
drugs
revised
fed
reg
fda
internal
procedures
recognize
office
generic
drugs
consult
fda
components
labeling
reviews
manual
policies
procedures
may
consultations
involving
possible
serious
safety
concerns
receive
highest
priority
decision
eighth
circuit
suggested
manufacturers
show
impossibility
federal
law
merely
permitted
sell
generic
drugs
require
see
mensing
wyeth
generic
defendants
compelled
market
metoclopramide
realized
label
insufficient
believe
even
propose
label
change
simply
stopped
selling
product
see
also
geier
american
honda
motor
describing
case
impossibility
one
state
law
penalizes
federal
law
requires
emphasis
added
respondents
advanced
argument
find
unnecessary
consider
time
respondents
cause
action
arose
fda
authority
require
manufacturer
change
label
received
authority
see
pub
stat
supp
iii
equally
significant
authority
withdraw
manufacturer
permission
market
drug
manufacturer
refused
make
requested
labeling
change
see
ed
cfr
manufacturer
ability
comply
duty
warn
depend
unilateral
actions
period
changed
label
fda
approved
disapproved
label
change
claim
wyeth
appear
arisen
period
respondents
claim
manufacturers
required
ask
fda
assistance
changing
labels
role
fda
arises
result
manufacturers
defense
cases
involve
situation
manufacturer
produces
generic
drugs
see
okie
multinational
medicines
ensuring
drug
quality
era
global
eng
med
see
also
gpha
frequently
asked
questions
generics
http
companies
make
half
generic
drugs
case
manufacturer
independently
change
label
cbe
regulation
triggering
corresponding
change
generic
label
justice
thomas
author
today
opinion
previously
expressed
view
obstacle
inconsistent
constitution
see
williamson
mazda
motor
america
opinion
concurring
judgment
slip
wyeth
levine
opinion
concurring
judgment
position
however
accepted
thus
justify
majority
novel
expansion
impossibility
author
law
review
article
proposing
theory
supremacy
clause
acknowledges
much
see
nelson
preemption
rev
non
obstante
provision
rejects
artificial
presumption
congress
intend
contradict
state
laws
federal
statutes
must
therefore
harmonized
state
law
plurality
hand
carefully
avoids
discussing
ramifications
new
theory
longstanding
presumption
according
gpha
fda
generic
drug
industry
spend
millions
dollars
year
seeking
reassure
consumers
affordable
generic
drugs
really
federal
law
compels
pricier
counterparts
brief
gpha
amicus
curiae
pet
cert
nos
pp
